Expresión de receptores a factor de crecimiento insulínico tipo I, c-fos y PCNA en un tumor mamario experimental / Expression to an insulin growth factor type I receptor, c-fos and Nuclear Antigen of cellular proliferatium in an experimental mammary tumor

Las terapias oncológicas conllevan generalmente efectos secundarios indeseados por lo que el mejor conocimiento de los mecanismos regulatorios del desarrollo y crecimiento tumoral puede abrir el camino a enfoques terapeúticos más adecuados. El objetivo de éste trabajo fue profundizar el estudio de la implicancia de factores que regulan el crecimiento del cáncer mamario empleando un modelo experimental químicamente inducido en rata, el que presenta similitudes con el cáncer mamario humano principalmente en lo que respecta a la regulación hormonal de su crecimiento. El tumor mamario fue inducido químicamente en ratas normales y diabéticas. Se analizó la expresión de receptores a factor de crecimiento insulínico tipo I (RIGF-I), el que forma parte de un sistema formado por factores de crecimiento, sus receptores y proteínas transportadas; éste sistema se encuentra alterado en pacientes con diabetes mellitus no dependiente de insulina. También se analizó la expresión de las proteínas c-FOS y PCNA (antígeno nuclear de proliferación celular), ambas relacionadas con la proliferación celular. Los resultados experimentales mostraron significativas diferencias en los tumores mamarios desarrollados: los de las ratas diabéticas presentaron mayor período de latencia (p<0,001), menor número de tumores desarrollados por rata (p<0,02) y una velocidad de crecimiento menor (p<0,05) con respecto a los tumores desarrollados en ratas normales. Asimismo, mostraron un patrón histológico de marcada benignidad, en contraste con los adenocarcinomas malignos ductales desarrollados en los animales normales. La expresión de las proteínas c-FOS y PCNA detectada por métodos inmunohistoquímicos fue significativamente menor en los tumores de las ratas diabéticas que en ratas normales. En cuanto a la expresión de RIGF-I, los resultados indicaron que la misma estaría regulada por las hormonas esteroides en animales diabéticos y normales. El trabajo permitió analizar experimentalmente la interrelación entre factores de crecimiento insulínicos y hormonas esteroides en el desarrollo y crecimiento tumoral mamario, particularmente cuando están presentes la patología mamaria y la diabetes (AU)

Expresión de receptores a factor de crecimiento insulínico tipo I, c-fos y PCNA en un tumor mamario experimental / Expression to an insulin growth factor type I receptor, c-fos and Nuclear Antigen of cellular proliferatium in an experimental mammary tumor

Las terapias oncológicas conllevan generalmente efectos secundarios indeseados por lo que el mejor conocimiento de los mecanismos regulatorios del desarrollo y crecimiento tumoral puede abrir el camino a enfoques terapeúticos más adecuados. El objetivo de éste trabajo fue profundizar el estudio de la implicancia de factores que regulan el crecimiento del cáncer mamario empleando un modelo experimental químicamente inducido en rata, el que presenta similitudes con el cáncer mamario humano principalmente en lo que respecta a la regulación hormonal de su crecimiento. El tumor mamario fue inducido químicamente en ratas normales y diabéticas. Se analizó la expresión de receptores a factor de crecimiento insulínico tipo I (RIGF-I), el que forma parte de un sistema formado por factores de crecimiento, sus receptores y proteínas transportadas; éste sistema se encuentra alterado en pacientes con diabetes mellitus no dependiente de insulina. También se analizó la expresión de las proteínas c-FOS y PCNA (antígeno nuclear de proliferación celular), ambas relacionadas con la proliferación celular. Los resultados experimentales mostraron significativas diferencias en los tumores mamarios desarrollados: los de las ratas diabéticas presentaron mayor período de latencia (p<0,001), menor número de tumores desarrollados por rata (p<0,02) y una velocidad de crecimiento menor (p<0,05) con respecto a los tumores desarrollados en ratas normales. Asimismo, mostraron un patrón histológico de marcada benignidad, en contraste con los adenocarcinomas malignos ductales desarrollados en los animales normales. La expresión de las proteínas c-FOS y PCNA detectada por métodos inmunohistoquímicos fue significativamente menor en los tumores de las ratas diabéticas que en ratas normales. En cuanto a la expresión de RIGF-I, los resultados indicaron que la misma estaría regulada por las hormonas esteroides en animales diabéticos y normales. El trabajo permitió analizar experimentalmente la interrelación entre factores de crecimiento insulínicos y hormonas esteroides en el desarrollo y crecimiento tumoral mamario, particularmente cuando están presentes la patología mamaria y la diabetes

An experimental model of diabetes and cancer in rats.

The aim of this study was to develop an experimental model for the study of cancer associated with diabetes. For diabetes induction, Sprague-Dawley rats were given streptozotocin (STZ, 90 mg/kg body weight (BW), by intraperitoneal injection on the second day of life. For mammary tumour induction, rats were injected with 50 mg/kg BW of N-nitroso-N-methylurea (NMU) at 50, 80 and 110 days old. The neoplastic process and the effect of tamoxifen treatment was examined in non-diabetic and diabetic rats. The latency period, NMU-induced tumour incidence and the number of tumours per rat in diabetic rats versus controls were 117 +/- 7 days versus 79 +/- 9 days (P < 0.001); 93% versus 95% (NS); and 5.2 +/- 1.6 versus 2.7 +/- 0.5 (P < 0.02). A more benign histological pattern for tumours in diabetic animals was observed. Mammary tumours in diabetic rats grew more slowly than in controls. Tamoxifen (1 mg/kg/day) treated diabetic rats showed tumour regression in 67% of NMU-induced mammary tumours versus 53% in controls (NS). Our results show that tumour progression seems to be affected by diabetes in this experimental model. We suggest this is the result of changes to insulin-like growth factors and their receptors, which occur in diabetics, and our future research will examine this hypothesis.

Effects on mouse uterus of three antitumoral drugs acting upon estrogen and progesterone receptors directly and through other transduction pathways.

Three antitumoral drugs, tamoxifen (Tam), medroxyprogesterone acetate (MPA), and 8-Cl-cyclic AMP (8Cl), were administered separately and in combination to normal adult mice in order to record their effects on uterus weight, on estrous cycle, and on two estrogen receptor (ER) and progesterone receptor (PgR) parameters, namely content and nucleo-cytoplasm distribution. Tam decreased uterus weight (49%) and total ER content (118+/-6 vs 328+/-20 fmol/mg protein in controls) but increased total PgR (1183+/-230 vs 743+/-52 fmol/mg protein in controls) and nuclear retention of ER and PgR. MPA down-regulated PgR content and increased uterus weight (36%), but failed to modify ER and PgR nuclear retention. The only parameter changed by 8Cl was nucleo-cytoplasm PgR distribution. Tam + MPA association produced the same results as Tam alone for ER and PgR nuclear retention, but receptor content was not significantly different from that of controls. Both drugs, administered separately, had opposite effects on PgR content; when both were acting concurrently, an algebraic addition of effects was observed, as if both transcription circuits were triggered independently. Remaining Tam effects, not modified by a combination with MPA, indicated the predominance of Tam on the corresponding parameters. When Tam and 8Cl were administered together, 8Cl counteracted the effect of Tam only on PgR content. When associated with MPA, 8Cl changed the effects of MPA on ER and PgR nuclear retention, whereas on receptor content, only that of ER was increased (502+/-47 vs 328+/-20 fmol/mg protein in controls). These crossed effects indicate that interrelations between different transduction pathways can affect certain functional circuits while sparing others. The possibility of acting pharmacologically upon different transcription pathways represents a novel approach to modify drug effects directed to specific transduction targets through cross-talk between their components.

Evaluation of a displacement assay with tamoxifen as prognostic indicator in breast-cancer patients with estrogen-receptor-positive tumors.

A displacement assay with tamoxifen, based on the relative binding affinity of tamoxifen and estradiol for the estrogen receptor (ER), was proposed in 1990 as prognostic indicator for breast-cancer patients. Validation of its predictive results in relation to the outcome of 73 patients with ER+ tumors is analyzed. ER, progesterone receptor (PgR) determinations and other conventional prognostic factors in relation to the displacement assay, were considered. Displacement assay results allowed ER+ tumors to be grouped as displaceable (D) or weakly displaceable (WD), with the implication that D tumors should respond better to tamoxifen (Tam) administration. Survival and disease-free interval curves showed highly significant differences between patients with ER+ D and ER+ WD tumors. For survival, including all tumor stages, 73.9% of patients were alive at 9 years after surgery in the group with D tumors and 37.0% in the group with WD tumors (p < 0.005); relative contribution of the different stages is analyzed. Addition of axillary-node number increased the prognostic significance of displacement categories for survival and disease-free interval. PgR determination as another ER functional expression failed to show significant differences for survival and disease-free interval between ER+ PgR+ and ER+ PgR- tumors. Thus, results from the displacement assay and from PgR determinations reflect 2 independent ER functional expressions. Displacement assay data appear as reliable prognostic indicators of breast-cancer outcome, and contribute to more appropriate treatment decisions in this pathology.

[New concepts on hormone dependence in breast cancer]. / Nuevos conceptos sobre hormonodependencia en el cáncer de mama.

The type of hormone dependence in mammary neoplasias is usually defined by the presence or absence of estrogen and progesterone receptors. At present, new advances in the knowledge related to the functionality of these receptors are changing our previous concepts. Estrogen receptors classified as negative by biochemical or immunocytochemical methods because of deletions or mutations in their ligand-binding domain, are still able to regulate the expression of genes related to cellular proliferation. Receptors defined as positive, may present other defective domains with disappearance or distortion of their transcriptional function. As a result, regulation of the cellular proliferative process is distorted and the tumoral growth seems autonomous, as if the receptors were absent. The modular organization of the receptor molecule allows a relative functional independence of the constitutive domains. Functional assays to evaluate receptor behavior under different experimental or clinical situations are necessary. A displacement assay with tamoxifen, for studying the relative binding affinity of tamoxifen and estradiol for the estrogen receptor contributes to a more appropriate use of this antiestrogen in mammary oncology. Conformational changes and mutations in one or several of these genomic molecules may after the transcriptional message with repercussion on cellular proliferation. In this way, antiprogestinic agents can show progestin agonistic effects when combined with cAMP analogues; on the other hand, opposite effects on cellular growth by cAMP analogues can be observed according to the type of hormone dependency (autonomous or dependent) of the tumors. Modulation of steroid receptor transcriptional activity is also achieved through non-transcriptional proteins associated to the receptor molecule. These proteins are then potential targets for the pharmacological regulation of the transcription message. Resistance to antihormone treatments in breast cancer is a dominant feature in the evolution of this malignancy. It cannot be attributed to the presence or absence of steroid receptors when only defined by their quantitative variations.

Receptors characterization of intraperitoneally N-nitroso-N-methylurea-induced mammary tumors in rats.

Mammary adenocarcinomas induces in female Sprague-Dawley rats by three intraperitoneal injections of N-nitroso-N-methylurea were studied in order to characterize their estrogen (ER), progesterone (PgR), prolactin (PRLR) and epidermal growth factor (EGFR) receptors. All samples evaluated showed the presence of ER and PgR in the cytosol fraction and PRLR amd EGFR in the membrane fraction. Q (fmol/mg) and K(d) (nM) values were as follows: ER, 56 +/- 11 and 0.5 +/- 0.1; PgR, 109 +/- 25 and 2.2 +/- 0.5 and PRLR, 335 +/- 75 and 0.5 +/- 0.2, respectively. In all tumors studied, two specific sites were found for EGFR, one with Q(1) = 22 +/- 9 and K(d1) = 0.6 +/- 0.3, and the other with Q(2) = 125 +/- 33 and K(d2) = 2.1 +/- 0.5. Receptor content was found to be independent of tumor histopathological variety. Displacement index (DI) with estradiol and tamoxifen of [I(3)H]E2-ER binding showed great heterogeneity, with values ranging from 0.01 to1.54. No correlation between ER content and DI values was found. Antiestrogenic binding sites were not found in the microsomal fraction of ten mammary tumors examined. Proliferation of this experimental mammary tumor may be regulated by a complex interaction of steroid and polypeptide hormones, as well as growth factors.

Effect of tamoxifen on intraperitoneal N-nitroso-N-methylurea induced tumors.

The effect of tamoxifen (TAM) was evaluated on a mammary tumor model induced in Sprague-Dawley rats by intraperitoneal administration of three N-nitroso-N-methylurea (NMU) doses. Animals received TAM (1 mg/kg per day) from 10 days before the first NMU dose up to 140 days later. Thereafter, treatment was discontinued and the observation period was extended 60 days longer. Mean overall latency period, tumor number per rat and tumor incidence were recorded. Significant differences between treated and control batches were observed in tumor number per rat (1.8 +/- 1.1 versus 5.2 +/- 1.6; P < 0.05) and in tumor incidence (50% versus 100%; P < 0.05), respectively. No significant difference in latency period between both batches was recorded. All lesions induced in the control batch were malignant, whereas only 45% of those induced in TAM-treated animals were malignant and the remaining 55% were preneoplastic. At 60 days after treatment discontinuance, tumor incidence increased to 90% and also tumor number per rat increased to 4.6 +/- 1.5. TAM effect was also evaluated in rats with NMU-induced tumors by treatment with 1 mg/kg per day during 60 days starting when tumors reached a 1.5-cm diameter. Regression to less than 80% of initial size in 49% of the tumors was observed, while in ovariectomized rats, 33% of tumors regressed. Estrogen receptor content, ER (fmol/mg protein) and Kd (nM) in control tumors were: 56 +/- 10 and 0.5 +/- 0.1. In tumors of TAM-treated animals, ER was less than 5 fmol/mg protein. Findings demonstrate that TAM significantly decreased the appearance of tumors induced in rats by i.p. injection of NMU and when TAM treatment was initiated after tumor induction, some tumors failed to respond to hormonal manipulation. Differential tumor growth response after TAM or oophorectomy in each tumor indicates that in the same rat it is possible to distinguish hormone-dependent and hormone-autonomous tumor populations. Hormonal regulation of tumor growth can be under intrinsic control, regardless of the hormonal status of the whole organism.

Opposite effect of a cAMP analogue on tumoral growth related to hormone dependence of a murine mammary tumor.

Interactions among transcription factors are one of the mechanisms that regulate gene expression. Through protein-protein associations different signaling pathways become connected and the message triggered by each of the molecules involved can modify other related routes. In a murine mammary tumor induced by medroxyprogesterone acetate (MPA), further treatment with this agent showed a different response on tumor growth. In one group of tumors, growth rate was increased (hormone dependent, HD), whereas in the other group the progestin agent failed to modify the rate of tumor development (hormone autonomous, HA). Progesterone receptors (PgR) and estrogen receptors (ER) were expressed in both groups. Administration of 8-CI-cAMP, a cAMP analogue, stimulated tumor growth in the HD subline and inhibited growth in the HA subline. Simultaneous administration of 8-CI-cAMP and MPA resulted in suppression of inhibitory 8-CI-cAMP action in the HA tumor subline attributable to changes in molecular configuration of protagonic members of each signaling pathway, whereas in the HD subline growth was additive as if each of the pathways were acting separately. MPA induced down regulation of PgR in both tumor sublines and up regulation of ER in the C4-HD subline. The effect of 8-CI-cAMP alone or associated with MPA was more complex and variations in PgR and ER content by themselves are insufficient to explain changes in tumoral growth. A model consistent with our experimental findings is presented.

Factores de transcripción y diversidad proliferativa de las células neoplásicas / Transcription factors and proliferative diversity of neoplastic cells

el desarrollo del câncer es un proceso de etapas secuenciales, a saber: iniciación, promoción y progresión, en cada una de las cuales van surgiendo eslabones que favorecen los pasos siguientes. Cualquier agente puede actuar desencadenando la transformación maligna de células normales (iniciación) o bien, estimulando la proliferación de las células "iniciadas" (promoción) o bien, contribuyendo a la formación de la massa tumoral y a su posterior diseminación (progresión). Así, los receptores esteróideos, considerados clásicamente como promotores, pueden modificarse y actuar como iniciadores. Inversamente, cancerígenos químicos que en ciertas dosis son responsables de daños en el ADN que llevan a la transformación celular, en concentraciones menores pueden afectar a proteínas nucleares que desorganizan el nucleosoma, permitiendo que otros agentes, antes inocuos, desencadenen la transformación celular. Los factores de transcripción desempeñan un papel fundamental en la proliferación celular. Son proteínas con ciertas configuraciones estructurales que posibilitan su unión al ADN. Hay grupos o familias de estos factores que reconocen secuencias de nucleótidos denominadas "elementos respondedores" y que modulan la transcripción genómica de proteínas, entre ellas las relacionadas con la proliferación celular. Además de la interación proteínas-ADN, se establecen interrelaciones proteína-proteina entre estos factores, que pueden modificar el mensaje transcripcional...

Factores de transcripción y diversidad proliferativa de las células neoplásicas / Transcription factors and proliferative diversity of neoplastic cells

el desarrollo del cÔncer es un proceso de etapas secuenciales, a saber: iniciación, promoción y progresión, en cada una de las cuales van surgiendo eslabones que favorecen los pasos siguientes. Cualquier agente puede actuar desencadenando la transformación maligna de células normales (iniciación) o bien, estimulando la proliferación de las células "iniciadas" (promoción) o bien, contribuyendo a la formación de la massa tumoral y a su posterior diseminación (progresión). Así, los receptores esteróideos, considerados clásicamente como promotores, pueden modificarse y actuar como iniciadores. Inversamente, cancerígenos químicos que en ciertas dosis son responsables de daños en el ADN que llevan a la transformación celular, en concentraciones menores pueden afectar a proteínas nucleares que desorganizan el nucleosoma, permitiendo que otros agentes, antes inocuos, desencadenen la transformación celular. Los factores de transcripción desempeñan un papel fundamental en la proliferación celular. Son proteínas con ciertas configuraciones estructurales que posibilitan su unión al ADN. Hay grupos o familias de estos factores que reconocen secuencias de nucleótidos denominadas "elementos respondedores" y que modulan la transcripción genómica de proteínas, entre ellas las relacionadas con la proliferación celular. Además de la interación proteínas-ADN, se establecen interrelaciones proteína-proteina entre estos factores, que pueden modificar el mensaje transcripcional...(AU)

Estrogen receptor isoforms and progestin hormone dependence in a mouse mammary tumor model.

The close interaction between receptors and other transcription factors suggests that their corresponding transducing signals can trigger functional and structural changes in other related molecules. The effect of a progestinic agent, medroxyprogesterone acetate (MPA), on some of the estrogen-receptor (ER) parameters was studied in 2 murine mammary tumor sublines with different progestin hormone dependence for their respective growth. The relative binding affinity of estradiol and tamoxifen for the ER, the receptor content and the ER isoforms studied by HPLC were determined in the hormone-autonomous (HA) and the hormone-dependent (HD) tumor sublines. In the HA subline administration of MPA did not modify the tumor growth rate, whereas this was accelerated in the HD subline. The ER content was clearly increased in the HD tumor subline, but not in the HA subline, compared with the untreated controls. In contrast, the E2 and tamoxifen relative binding affinity for the ER and the isoform profiles were affected by MPA treatment in the HA, but not in the HD tumor subline. The functional change (decrease in relative binding affinity) can be attributed to the appearance of a lower-molecular-size ER isoform under the progestinic treatment. Modifications in one receptor molecule by the action of ligands corresponding to another type of receptor show the interconection between transcription factors and the necessity of broadening conventional concepts regarding hormone dependence in mammary tumorigenesis.

[Transcription factors and proliferative diversity of neoplastic cells]. / Factores de transcripción y diversidad proliferativa de las células neoplásicas.

Cancer is a multistage process with sequential steps: initiation, promotion, progression. However, the distinction between the agents that can trigger any of these processes is less clear, depending on doses, biological stage of the tissue, molecular interactions, genomic and somatic mutation, etc. Thus, steroid receptors, classically considered as promoters, could be acting as initiators under different alterations. On the other hand, chemical carcinogens that can produce DNA damage leading to cellular transformation, in lower dosage are able to alter nuclear proteins which in turn favor the action of other agents triggering the initiation process. Transcription factors (TF) are nuclear proteins with particular structural configurations for their interaction with DNA. There are families of TF with specificity for certain nucleotide sequences called "response elements". The association TF-DNA response elements modulate the genomic transcription and synthesis of proteins, many of which are related to cellular proliferation. The transcriptional message can also be influenced by TF protein-protein interactions, besides their association with the response elements. This "cross-talk" or "side regulation" becomes an important genomic regulatory mechanism. Certain biochemical signals acting on particular proteins (receptors, enzymes) can then trigger biological effects attributable to other proteins. Another transcriptional regulatory mechanism is the cytoplasm-nucleus shuttling of TF according to the cellular replication rhythm and other metabolic cellular requirements. These recent advances open new vistas for the pharmacological attack to the proliferative diversity of neoplastic cells.

Factores de transcripción y diversidad proliferativa de las células neoplásicas. / [Transcription factors and proliferative diversity of neoplastic cells]

Cancer is a multistage process with sequential steps: initiation, promotion, progression. However, the distinction between the agents that can trigger any of these processes is less clear, depending on doses, biological stage of the tissue, molecular interactions, genomic and somatic mutation, etc. Thus, steroid receptors, classically considered as promoters, could be acting as initiators under different alterations. On the other hand, chemical carcinogens that can produce DNA damage leading to cellular transformation, in lower dosage are able to alter nuclear proteins which in turn favor the action of other agents triggering the initiation process. Transcription factors (TF) are nuclear proteins with particular structural configurations for their interaction with DNA. There are families of TF with specificity for certain nucleotide sequences called [quot ]response elements[quot ]. The association TF-DNA response elements modulate the genomic transcription and synthesis of proteins, many of which are related to cellular proliferation. The transcriptional message can also be influenced by TF protein-protein interactions, besides their association with the response elements. This [quot ]cross-talk[quot ] or [quot ]side regulation[quot ] becomes an important genomic regulatory mechanism. Certain biochemical signals acting on particular proteins (receptors, enzymes) can then trigger biological effects attributable to other proteins. Another transcriptional regulatory mechanism is the cytoplasm-nucleus shuttling of TF according to the cellular replication rhythm and other metabolic cellular requirements. These recent advances open new vistas for the pharmacological attack to the proliferative diversity of neoplastic cells.

Characterization of rat uterine estrogen receptors in vivo.

In vivo binding of [3H]estradiol ([3H]E2) in the rat uterus was performed by an intraluminal perfusion of the ligand for different time periods. In this way the binding takes place in the intact organ before processing the tissue. In 10 min, with 10 nM [3H]E2 apparent saturation or steady state incorporation of the [3H]E2 was achieved with a similar distribution of the label between cytosol and nuclear fractions. In vitro, the subcellular localization of the estrogen receptor (ER) is influenced by the extent of tissue damage. With the intact organ the ER subcellular distribution approaches that of the in vivo perfusion. With increasing [3H]E2 in the perfusate it was possible to obtain a "saturation" curve and to derive the kinetic parameters. For cytosol: Kd 16 nM; Bmax 235 fmol/mg prot. For nucleus: Kd 2.7 nM; Bmax 103 fmol/mg prot. To follow the time course of the ER movement in vivo, "pulse and wait" experiments were designed. Both uterine horns were perfused for 1 min. One of the horns was immediately processed (0 time) and the other was left in place after the perfusion for different periods. At 0 time 90% of the bound label appeared in the cytosol. At 5, 15 and 30 min, the label in the cytosol decreased and that of the nucleus increased approx. to 50%. Thus, translocation of the bound label from cytosol to nucleus was apparent. The role of the cytoplasm-nucleus ER traffic in the regulation of gene transcription by estrogens is discussed.

Evolución de pacientes con mejor pronóstico en cáncer de mama / Evolution of patients with best prognosis in breast cancer

En una serie de 23 pacientes seguidas durante 4 y 5 años, se pudo constatar una alta correlación entre aquellas con tumores RE+ desplazables y la evolución favorables de su enfermedad (11 de 12 casos - 91 por ciento), así como una correlación entre los tumores RE+ poco desplazables y la evolución desfavorable de la enfermedad (3 de 4 casos - 75 por ciento). Este último grupo se homologa con los tumores RE - cuya evolución fue desfavorable. En esta serie, los tumores RE+ de las pacientes con evolución favorable, presentaron valores de RPg mayores de los RE (10 de 12 casos - 83 por ciento). En las pacientes con tumores RE+ la evolución desfavorable, los valores de RPg no fueron mayores que RE (3 de 4 casos - 75 por ciento). Los estudios anatomo-patológicos indicaron que los tumores RE+ desplazables presentaron mayor proporción de células más diferenciadas que el grupo de tumores RE. Los otros indicadores histológicos examinados: necrosis, desmoplasia, invasión linfocitaria, no mostraron correlación con grado de dependencia hormonal ni con la prueba de desplazamiento por Tam

Evolución de pacientes con mejor pronóstico en cáncer de mama / Evolution of patients with best prognosis in breast cancer

En una serie de 23 pacientes seguidas durante 4 y 5 años, se pudo constatar una alta correlación entre aquellas con tumores RE+ desplazables y la evolución favorables de su enfermedad (11 de 12 casos - 91 por ciento), así como una correlación entre los tumores RE+ poco desplazables y la evolución desfavorable de la enfermedad (3 de 4 casos - 75 por ciento). Este último grupo se homologa con los tumores RE - cuya evolución fue desfavorable. En esta serie, los tumores RE+ de las pacientes con evolución favorable, presentaron valores de RPg mayores de los RE (10 de 12 casos - 83 por ciento). En las pacientes con tumores RE+ la evolución desfavorable, los valores de RPg no fueron mayores que RE (3 de 4 casos - 75 por ciento). Los estudios anatomo-patológicos indicaron que los tumores RE+ desplazables presentaron mayor proporción de células más diferenciadas que el grupo de tumores RE. Los otros indicadores histológicos examinados: necrosis, desmoplasia, invasión linfocitaria, no mostraron correlación con grado de dependencia hormonal ni con la prueba de desplazamiento por Tam

Displacement by tamoxifen of the estradiol-estrogen receptor binding: a functional assay for breast cancer studies.

Displacement curves with estradiol (E2) and Tamoxifen (Tam) of the [3H]E2-ER binding in 49 ER+ mammary neoplasia showed a great heterogeneity suggesting the existence of more than one population of ER+ tumors when the relative binding affinity of both ligands for the ER was considered. The (D50E2/D50Tam) x 100 ratio was called Displacement Index (DI) with values asymmetrically distributed from 0.05 to 2.90. The range from 0.18 to 0.54 was adopted as central interval given by the median +/- SE (median: 0.36; SE: 0.09). DI values below 0.18 (24% of the tumors in our series) were considered as "lower", indicating that higher Tam doses would be necessary to displace the E2-ER binding. The potency of Tam as displacer is dependent not only of its own affinity for the ER, but also of that of E2 for the same receptor. The DI expresses their relative binding "strength". DI values were not correlated with ER and progesterone receptor content nor with the D50 Tam and D50E2 taken separately. Antiestrogen binding sites (AEBS) were determined in the cytosol (AEBSc) and in the microsomal fraction of 10 ER+ tumors from our series. The AEBSc/ER ratio was inversely correlated with the DI, that is, displacement of 3HE2 from the E2-ER complex by Tam would be lower in tumors with higher AEBSc/ER ratio. The DI is another parameter to be considered in the study of the sensitivity of breast neoplasias to antiestrogen treatments.